Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection

JAMA Pediatrics

Volumn 170, Issue 12, 2016, Pages 1173-1180

  Gantt, Soren ^a,b   Dionne, Francois ^c   Kozak, Fred K ^a,b   Goshen, Oran ^a   Goldfarb, David M ^a,b   Park, Albert H ^d   Boppana, Suresh B ^e,f   Fowler, Karen ^e,g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

^c Centre for Clinical Epidemiology and Evaluation   (Canada)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VALGANCICLOVIR;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CHILD; COCHLEA PROSTHESIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONGENITAL INFECTION; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; HEALTH CARE COST; HEARING IMPAIRMENT; HIGH RISK INFANT; HUMAN; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAID; NEWBORN; NEWBORN SCREENING; OUTCOME ASSESSMENT; PERINATAL PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TARGETED NEWBORN SCREENING; UNITED STATES; UNIVERSAL NEWBORN SCREENING; YOUNG ADULT; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTIONS; ECONOMICS; HEARING LOSS; PARENT; PSYCHOLOGY; SATISFACTION; VIROLOGY;

COST SAVINGS; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTIONS; EARLY DIAGNOSIS; HEARING LOSS; HUMANS; INFANT; INFANT, NEWBORN; MEDICAID; NEONATAL SCREENING; PARENTS; PERSONAL SATISFACTION; PROSPECTIVE STUDIES; UNITED STATES;

EID: 85011344909     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2016.2016     Document Type: Article

References (49)

1. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253-276.
2. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: National Academies Press; 2000.
3. Cannon MJ, Griffiths PD, Aston V, Rawlinson WD. Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit? Rev Med Virol. 2014;24(5):291-307.
4. Morton CC, Nance WE. Newborn hearing screening: a silent revolution. N Engl J Med. 2006; 354(20):2151-2164.
5. Goderis J, De Leenheer E, Smets K, Van Hoecke H, Keymeulen A, Dhooge I. Hearing loss and congenital CMV infection: a systematic review. Pediatrics. 2014;134(5):972-982.
6. Foulon I, Naessens A, FoulonW, Casteels A, Gordts F. A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection. J Pediatr. 2008;153(1):84-88.
7. Fowler KB. Congenital cytomegalovirus infection: audiologic outcome. Clin Infect Dis. 2013; 57(suppl 4):S182-S184.
8. Boppana SB, Ross SA, ShimamuraM, et al; National Institute on Deafness and Other Communication Disorders CHIMES Study. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med. 2011;364(22):2111-2118.
9. Yow MD, Demmler GJ. Congenital cytomegalovirus disease: 20 years is long enough. N Engl J Med. 1992;326(10):702-703.
10. Buchheit J, Marshall GS, Rabalais GP, Dobbins GJ. Congenital cytomegalovirus disease in the Louisville area: a significant public health problem. J Ky Med Assoc. 1994;92(10):411-415.
11. Larke RP, Wheatley E, Saigal S, Chernesky MA. Congenital cytomegalovirus infection in an urban Canadian community. J Infect Dis. 1980;142(5):647-653.
12. Townsend CL, Peckham CS, Tookey PA. Surveillance of congenital cytomegalovirus in the UK and Ireland. Arch Dis Child Fetal Neonatal Ed. 2011;96(6):F398-F403.
13. VaudryW, Lee BE, Rosychuk RJ. Congenital cytomegalovirus infection in Canada: active surveillance for cases diagnosed by paediatricians. Paediatr Child Health. 2014;19(1):e1-e5.
14. Sorichetti B, Goshen O, Pauwels J, et al. Symptomatic congenital cytomegalovirus infection is underdiagnosed in British Columbia. J Pediatr. 2016;169:316-317.
15. Kimberlin DW, Jester PM, Sánchez PJ, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372(10):933-943.
16. Boppana SB, Ross SA, Novak Z, et al; National Institute on Deafness and Other Communication Disorders CMV and Hearing Multicenter Screening (CHIMES) Study. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA. 2010;303(14):1375-1382.
17. Williams EJ, Kadambari S, Berrington JE, et al. Feasibility and acceptability of targeted screening for congenital CMV-related hearing loss. Arch Dis Child Fetal Neonatal Ed. 2014;99(3):F230-F236.
18. Duval M, Park AH. Congenital cytomegalovirus: what the otolaryngologist should know. Curr Opin Otolaryngol Head Neck Surg. 2014;22(6):495-500.
19. Williams EJ, Gray J, Luck S, et al. First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by congenital CMV infection. Arch Dis Child Fetal Neonatal Ed. 2015;100(6):F501-F506.
20. Bergevin A, Zick CD, McVicar SB, Park AH. Cost-benefit analysis of targeted hearing directed early testing for congenital cytomegalovirus infection. Int J Pediatr Otorhinolaryngol. 2015;79 (12):2090-2093.
21. Centers for Disease Control and Prevention. Annual data Early Hearing Detection and Intervention (EHDi) Program. Summary of 2011-2013 national CDC EHDi data. http://www.cdc .gov/ncbddd/hearingloss/ehdi-data.html. Updated October 23, 2015. Accessed December 28, 2015.
22. Dahle AJ, Fowler KB,Wright JD, Boppana SB, BrittWJ, Pass RF. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J AmAcad Audiol. 2000;11(5): 283-290.
23. Pinninti SG, Ross SA, ShimamuraM, et al; National Institute on Deafness and Other Communication Disorders CMV and Hearing Multicenter Screening (CHIMES) Study. Comparison of saliva PCR assay versus rapid culture for detection of congenital cytomegalovirus infection. Pediatr Infect Dis J. 2015;34(5):536-537.
24. American Academy of Pediatrics, Joint Committee on Infant Hearing. Year 2007 position statement: principles and guidelines for early hearing detection and intervention programs. Pediatrics. 2007;120(4):898-921.
25. Park AH, Duval M, McVicar S, Bale JF, Hohler N, Carey JC. A diagnostic paradigm including cytomegalovirus testing for idiopathic pediatric sensorineural hearing loss. Laryngoscope. 2014;124 (11):2624-2629.
26. Kimberlin DW, Aban I, Acosta EP. Valganciclovir for congenital cytomegalovirus. N Engl J Med. 2015;372(25):2463.
27. Gwee A, Curtis N, Garland SM, Connell TG, Daley AJ. Question 2: which infants with congenital cytomegalovirus infection benefit from antiviral therapy? Arch Dis Child. 2014;99(6):597-601.
28. Kimberlin DW, Lin CY, Sánchez PJ, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003;143(1):16-25.
29. Yoshinaga-Itano C. Early intervention after universal neonatal hearing screening: impact on outcomes. Ment Retard Dev Disabil Res Rev. 2003;9 (4):252-266.
30. Kennedy CR,McCann DC, Campbell MJ, et al. Language ability after early detection of permanent childhood hearing impairment. N Engl J Med. 2006; 354(20):2131-2141.
31. Staller SJ, Beiter AL, Brimacombe JA, Mecklenburg DJ, Arndt P. Pediatric performance with the Nucleus 22-channel cochlear implant system.AmJOtol. 1991;12(suppl):126-136.
32. American Speech-Language-Hearing Association. The prevalence and incidence of hearing loss in children. http://www.asha.org/public /hearing/Prevalence-and-Incidence-of-Hearing-Loss-in-Children/. Accessed December 28, 2015.
33. National Institute on Deafness and Other Communication Disorders. Cochlear implants. https://www.nidcd.nih.gov/health/hearing/pages /coch.aspx. Updated May 3, 2016. Accessed December 28, 2015.
34. Sorkin DL, Buchman CA. Cochlear implant access in six developed countries. Otol Neurotol. 2016;37(2):e161-e164.
35. Mohr PE, Feldman JJ, Dunbar JL. The societal costs of severe to profound hearing loss in the United States. Policy Anal Brief H Ser. 2000; 2(1):1-4.
36. Chambers JG, Shkolnik J, Pérez M. Special Education Expenditure Project: total expenditures for students with disabilities, 1999-2000: spending variation by disability. http://csef.air.org /publications/seep/national/final-seep-report-5.pdf. Published June 2003. Accessed September 9, 2016.
37. National CMV Foundation. CVM legislation. https://www.nationalcmv.org/cmv-research /legislation.aspx. Accessed May 4, 2016.
38. Chemaly RF, Ullmann AJ, Stoelben S, et al; AIC246 Study Team. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370(19):1781-1789.
39. Marty FM, Winston DJ, Rowley SD, et al; CMX001-201 Clinical Study Group. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369(13):1227-1236.
40. clinicaltrials.gov. Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir Therapy. NCT01649869. https: //clinicaltrials.gov/ct2/show/NCT01649869. Accessed November 24, 2015.
41. Bilavsky E, Shahar-Nissan K, Pardo J, Attias J, Amir J. Hearing outcome of infants with congenital cytomegalovirus and hearing impairment. Arch Dis Child. 2016;101(5):433-438.
42. Centers for Disease Control and Prevention (CDC). Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment: United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(3):57-59.
43. BakerMW, Laessig RH, Katcher ML, et al. Implementing routine testing for severe combined immunodeficiency within Wisconsin's newborn screening program. Public Health Rep. 2010;125(suppl 2):88-95.
44. Saavedra-Matiz CA, Isabelle JT, Biski CK, et al. Cost-effective and scalable DNA extraction method from dried blood spots. Clin Chem. 2013;59(7): 1045-1051.
45. Chan DK. Congenital hearing loss: a silent epidemic. https://pediatrics.ucsf.edu/blog /congenital-hearing-loss-silent-epidemic# .V8XJPUJTFaQ. Updated March 24, 2014. Accessed December 21, 2015.
46. Grosse S. Education cost savings from early detection of hearing loss: new findings. Volta Voices. 2007;14(6):38-40.
47. Din ES, Brown CJ, Grosse SD, et al. Attitudes toward newborn screening for cytomegalovirus infection. Pediatrics. 2011;128(6):e1434-e1442.
48. Fowler K, Mixon E, Brumbach AE, Kempf MC, Ross SA, Boppana S. Acceptability of newborn cytomegalovirus (CMV) screening in women: findings from the NIDCD CHIMES study. Presented at: Cytomegalovirus Public Health and Policy Conference; September 27, 2014; Salt Lake City, Utah.
49. Wilson JM, Jungner YG. Principles and practice of mass screening for disease [in Spanish]. Bol Oficina Sanit Panam. 1968;65(4):281-393.